Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment.
AffiliationDepartment of Respiratory Medicine, Waterford Regional Hospital, Waterford,, Ireland.
Cystic Fibrosis Transmembrane Conductance Regulator/*physiology
MetadataShow full item record
CitationChest. 2011 Jun;139(6):1480-90.
AbstractRecent advances in basic science have greatly expanded our understanding of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR), the chloride and bicarbonate channel that is encoded by the gene, which is mutated in patients with CF. We review the structure, function, biosynthetic processing, and intracellular trafficking of CFTR and discuss the five classes of mutations and their impact on the CF phenotype. The therapeutic discussion is focused on the significant progress toward CFTR mutation-specific therapies. We review the results of encouraging clinical trials examining orally administered therapeutics, including agents that promote read-through of class I mutations (premature termination codons); correctors, which overcome the CFTR misfolding that characterizes the common class II mutation F508del; and potentiators, which enhance the function of class III or IV mutated CFTR at the plasma membrane. Long-term outcomes from successful mutation-specific treatments could finally answer the question that has been lingering since and even before the CFTR gene discovery: Will therapies that specifically restore CFTR-mediated chloride secretion slow or arrest the deleterious cascade of events leading to chronic infection, bronchiectasis, and end-stage lung disease?
- New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
- Authors: Bell SC, De Boeck K, Amaral MD
- Issue date: 2015 Jan
- Repairing the basic defect in cystic fibrosis - one approach is not enough.
- Authors: Farinha CM, Matos P
- Issue date: 2016 Jan
- F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
- Authors: Yang H, Ma T
- Issue date: 2015
- Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
- Authors: Cai ZW, Liu J, Li HY, Sheppard DN
- Issue date: 2011 Jun
- Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.
- Authors: Sloane PA, Rowe SM
- Issue date: 2010 Nov